<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00447356</url>
  </required_header>
  <id_info>
    <org_study_id>E1697</org_study_id>
    <nct_id>NCT00447356</nct_id>
  </id_info>
  <brief_title>High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma</brief_title>
  <official_title>Phase III Randomized Study of Four Weeks High Dose IFN-2b in StageT3-T4 or N1 (Microscopic) Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hackensack Meridian Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Hackensack Meridian Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase III trial is studying high dose interferon alfa to see how well it&#xD;
      works compared to observation only in treating patients with stage II or stage III melanoma&#xD;
      that has been completely removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interferon alfa may interfere with growth of cancer cells. It is not yet known whether&#xD;
      treatment with interferon alfa is more effective than observation alone for stage II or stage&#xD;
      III melanoma that has been completely removed surgically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    There were no patient enrolled in this study at this site&#xD;
  </why_stopped>
  <start_date>January 2000</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed primary melanoma of cutaneous origin&#xD;
&#xD;
          -  Stage II (T3 N0 M0 1.5-4.0mm Breslow depth&#xD;
&#xD;
          -  Clinically negative regional lymph node pathologic status unkown OR&#xD;
&#xD;
          -  Histologically negative regional lymph nodes&#xD;
&#xD;
          -  Stage III (T4 N0 M0)&#xD;
&#xD;
          -  Greater than 4.0mm Breslow depth OR&#xD;
&#xD;
          -  Stage III (T1-4 N1)&#xD;
&#xD;
          -  One lymph node positive microscopically&#xD;
&#xD;
          -  Patients must meet at least 1 of the following criteria&#xD;
&#xD;
          -  T2b N0 primary melanoma 1.01-2.0mm with ulceration, node negative&#xD;
&#xD;
          -  T3a-b N0 primary melanoma 2.01-4.0mm with and without ulceration, node negative&#xD;
&#xD;
          -  T4a-b N0 primary melanoma &gt; 4.0mm with and without ulceration, node negative&#xD;
&#xD;
          -  T1aN1a-2a (microscopic)-primary melanoma of any thickness with microscopically&#xD;
             positive lymph node (any number)&#xD;
&#xD;
          -  Note EORTC patients who are node negative T2 or T3 are ineligible&#xD;
&#xD;
          -  Patients with positive sentinel node should undergo complete lymphadenectomy of the&#xD;
             nodal basin prior to study&#xD;
&#xD;
          -  Must complete all primary therapy (wide excision with or without lymphadenectomy) and&#xD;
             be randomized in the study within 84 days of wide excision&#xD;
&#xD;
          -  No clinical, radiological/laboratory, or pathological evidence of incompletely&#xD;
             resected melanoma or any distant metastatic disease&#xD;
&#xD;
          -  No clinically palpable lymphadenopathy&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance Status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 125,000/mm^3&#xD;
&#xD;
          -  Hematocrit at least 30%&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2 times the upper limit of normal (ULN)&#xD;
&#xD;
          -  AST, LDH, and Alkaline phosphate no greater than 2 times ULN&#xD;
&#xD;
          -  If lactate dehydrogenase or alkaline phosphate is above normal, a contrast enhanced CT&#xD;
             scan or MRI of the liver is required to document the absence of tumor&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  BUN no greater than 33mg/dl OR&#xD;
&#xD;
          -  Creatinine no greater than 1.8mg/dl&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No history of active ischemic heart disease&#xD;
&#xD;
          -  No cerebrovascular disease&#xD;
&#xD;
          -  No congestive heart failure(New York Heart Association class III or IV heart disease)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Biologic Therapy:&#xD;
&#xD;
          -  No prior immunotherapy including tumor vaccines, interferon, interleukins,levamisole,&#xD;
             or other biologic response modifers for melanoma Chemotherapy&#xD;
&#xD;
          -  No prior or concurrent chemotherapy Endocrine Therapy&#xD;
&#xD;
          -  No concurrent systemic corticosteriods including oral steriods (i.e., prednisone,&#xD;
             dexamethasone), topical steroid creams or ointments, or any steriod-containing&#xD;
             inhalers.&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No Prior or concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent immunosuppressive medications&#xD;
&#xD;
          -  No other history of invasive melanoma&#xD;
&#xD;
          -  No autoimmune disorders or conditions of immunosuppression&#xD;
&#xD;
          -  No other concurrent or prior malignancies within past 5 years&#xD;
&#xD;
          -  Cancer in situ&#xD;
&#xD;
          -  Lobular carcinoma in situ of breast&#xD;
&#xD;
          -  Carcinoma in situ of the cervix&#xD;
&#xD;
          -  Atypical melanocytic hyperplasia or Clark 1 melanoma in situ&#xD;
&#xD;
          -  Basal or squamous cell skin cancer&#xD;
&#xD;
          -  No evidence of organic brain syndrome or significant impairment of basal cognitive&#xD;
             function or any psychiatric disorder that would preclude study participation&#xD;
&#xD;
          -  No other significant medical or surgical condition, or any medication or treatment&#xD;
             regimens, that would interfere with study participation.&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>David S. Siegel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hackensack Meridian Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>March 12, 2007</study_first_submitted>
  <study_first_submitted_qc>March 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2007</study_first_posted>
  <last_update_submitted>May 9, 2013</last_update_submitted>
  <last_update_submitted_qc>May 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

